Active immunization to generate antibodies to solble a-beta
First Claim
Patent Images
1. A method of prophylaxis of a disease associated with amyloid deposits of Aβ
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
, wherein the fragment induces antibodies that specifically bind to Aβ
at one or more epitopes between residues 12 and 43 without inducing antibodies that specifically bind to one or more epitopes between residues 1-11, and the fragment is not Aβ
13-28, 17-28, 25-35, 35-40, 33-42 or 35-42, whereby the induced antibodies specifically bind to soluble Aβ
in the patient thereby inhibiting formation of amyloid deposits of Aβ
in the brain from the soluble Aβ
, and thereby effecting prophylaxis of the disease
11 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer'"'"'s disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit formation of amyloid deposits of A-beta in the brain of a patient from soluble Aβ thus preventing or treating the disease. Fragment A-beta 15-24 and subfragments of 5-10 contiguous amino acids thereof are preferred immunogens due to their capacity to generate a high titer of antibodies.
128 Citations
96 Claims
-
1. A method of prophylaxis of a disease associated with amyloid deposits of Aβ
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
, wherein the fragment induces antibodies that specifically bind to Aβ
at one or more epitopes between residues 12 and 43 without inducing antibodies that specifically bind to one or more epitopes between residues 1-11, and the fragment is not Aβ
13-28, 17-28, 25-35, 35-40, 33-42 or 35-42, whereby the induced antibodies specifically bind to soluble Aβ
in the patient thereby inhibiting formation of amyloid deposits of Aβ
in the brain from the soluble Aβ
, and thereby effecting prophylaxis of the disease - View Dependent Claims (6, 26, 28, 32)
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
-
2-5. -5. (canceled)
-
7. (canceled)
-
8. A method of prophylaxis of a disease associated with amyloid deposits of Aβ
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
, wherein the fragment is selected from the group consisting of Aβ
15-21, Aβ
16-22, Aβ
17-23, Aβ
18-24, Aβ
19-25, Aβ
15-22, Aβ
16-23, Aβ
17-24, Aβ
18-25, Aβ
15-23, Aβ
16-24, Aβ
17-25, Aβ
18-26, Aβ
15-24, Aβ
16-25, and Aβ
15-25, and thereby effect prophylaxis of the disease.
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
-
9-25. -25. (canceled)
-
27. (canceled)
-
29-31. -31. (canceled)
-
33-47. -47. (canceled)
-
48. A method of treating a disease associated with amyloid deposits of Aβ
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
, wherein the fragment induces antibodies that specifically bind to Aβ
at one or more epitopes between residues 12 and 43 without inducing antibodies that specifically bind to one or more epitopes between residues 1-11, and the fragment, 33-42 Aβ
13-28, 17-28, 25-35, 35-40 or 35-42, whereby the induced antibodies specifically bind to soluble Aβ
in the patient thereby inhibiting formation of amyloid deposits of Aβ
in the brain from the soluble Aβ
, and thereby treat the disease. - View Dependent Claims (53, 73, 75, 95)
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
-
49-52. -52. (canceled)
-
54. (canceled)
-
55. A method of treating a disease associated with amyloid deposits of Aβ
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
, wherein the fragment is selected from the group consisting of Aβ
15-21, Aβ
16-22, Aβ
17-23, Aβ
18-24, Aβ
19-25, Aβ
15-22, Aβ
16-23, Aβ
17-24, Aβ
18-25, Aβ
15-23, Aβ
16-24, Aβ
17-25, Aβ
18-26, Aβ
15-24, Aβ
16-25, and Aβ
15-25, and thereby treat the disease. - View Dependent Claims (79)
- in the brain of a patient, comprising administering an effective regime of a fragment of Aβ
-
56-72. -72. (canceled)
-
74. (canceled)
-
76-78. -78. (canceled)
-
80-94. -94. (canceled)
-
96-102. -102. (canceled)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeJanssen Alzheimer Immunotherapy (Johnson & Johnson), Wyeth LLC (Pfizer Inc.)
-
Original AssigneeWyeth LLC (Pfizer Inc.)
-
InventorsSeubert, Peter A, Vasquez, Nicki, Yednock, Ted
-
Application NumberUS10/544,093Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current424/185.100CPC Class CodesA61K 39/0007 Nervous system antigens; Pr...A61P 25/00 Drugs for disorders of the ...A61P 25/28 for treating neurodegenerat...A61P 37/04 ImmunostimulantsC07K 16/18 against material from anima...
